Level Four Advisory Services, LLC Apellis Pharmaceuticals, Inc. Transaction History

Level Four Advisory Services, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$55.39 - $72.47 $12,628 - $16,523	228 Added 2.18%	10,694 $628,000
Q4 2023 Feb 08, 2024	BUY	$37.14 - $64.82 $388,707 - $678,406	10,466 New	10,466 $626,000
Q2 2023 Jul 10, 2023	BUY	$76.68 - $93.31 $196,454 - $239,060	2,562 Added 69.66%	6,240 $568,000
Q1 2023 Jun 05, 2023	BUY	$46.59 - $66.96 $171,358 - $246,278	3,678 New	3,678 $242,000
Q3 2022 Nov 07, 2022	BUY	$44.76 - $69.66 $457,178 - $711,507	10,214 New	10,214 $698,000
Q3 2021 Oct 12, 2021	SELL	$31.4 - $69.84 $127,201 - $282,921	-4,051 Closed	0 $0
Q2 2021 Aug 09, 2021	BUY	$40.9 - $64.9 $165,685 - $262,909	4,051 New	4,051 $256,000

302

112M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.19B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Level Four Advisory Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Level Four Advisory Services, LLC with notifications on news.